| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
B Deoxyribonucleic Acid-Binding Activity in Human Fetal Membranes in Vitro
Department of Obstetrics and Gynecology, University of Melbourne, and Mercy Perinatal Research Center, Mercy Hospital for Women, East Melbourne, 3002 Victoria, Australia
Address all correspondence and requests for reprints to: Dr. Martha Lappas, Department of Obstetrics and Gynecology, University of Melbourne, Mercy Hospital for Women, 126 Clarendon Street, East Melbourne, 3002 Victoria, Australia. E-mail: mlappas{at}unimelb.edu.au.
| Abstract |
|---|
|
|
|---|
B (NF-
B) transcription pathway is activated by ROS and is a key regulator of PGs, proinflammatory cytokine release, and protease activity. N-Acetyl-cysteine (NAC) is an antioxidant that through its ability to scavenger ROS suppresses NF-
B DNA-binding activity and resultant gene expression. The aim of this study was to elucidate the effect of NAC on NF-
B DNA-binding activity, phospholipid metabolism, cytokine release, and protease activity from human fetal membranes. Human amnion and choriodecidua (n = 9 separate placentas) were treated with 0 (control), 5, 10, or 15 mM NAC in the presence of 10 µg/ml lipopolysaccharide. After 6-h incubation, the tissues were collected, NF-
B DNA binding activity was assessed by gel shift binding assays, and matrix metalloproteinase-9 and urokinase-type plasminogen activator activity were determined by zymography. The incubation medium was collected and assayed for type II phospholipase A2 tissue content, IL-6, IL-8, TNF
, and 8-isoprostane release by ELISA. The release of PGF2
was measured by RIA. Treatment of fetal membranes with NAC significantly suppressed lipopolysaccharide-stimulated type II phospholipase A2 release and content; PGF2
, IL-6, IL-8, TNF
, and 8-isoprostane release; and matrix metalloproteinase-9 and urokinase-type plasminogen activator enzyme activity and suppressed NF-
B DNA-binding activity (by ANOVA, P < 0.05). The data presented in this study demonstrate that NAC inhibits an NF-
B-activated pathway and subsequent phospholipid metabolism, proinflammatory cytokine release, and protease activity in human fetal membranes. | Introduction |
|---|
|
|
|---|
B (NF-
B).
NF-
B plays a pivotal role in inducing the expression of multiple genes involved in immune and inflammatory responses (reviewed in Ref. 6). In unstimulated cells, NF-
B dimers are found in an inactive form in the cytoplasm, bound with an inhibitory protein I
B. In response to activating signals, I
B-
undergoes phosphorylation by I
B kinases, ubiquitination, and subsequent proteasome-dependent degradation. Free NF-
B dimers then rapidly translocate to the nucleus to initiate transcription by high affinity binding to regulatory
B motifs in target genes. The
B motif has been identified in the promoter region of a number of genes involved in the initiation and progression of human preterm and term labor, including components of the phospholipid-metabolizing pathway [for example, phospholipase A2 (PLA2) and PGE2 production]; proinflammatory cytokines TNF
, IL-6, and IL-8; and proteases matrix metalloproteinase-9 (MMP-9) and urokinase-type plasminogen activator (uPA) (7, 8, 9, 10, 11, 12, 13, 14, 15).
Compounds that have antioxidant properties, such as N-acetyl-cysteine (NAC), have been shown to inhibit upstream events leading to NF-
B activation (16, 17, 18). NAC is a thiol-containing antioxidant that either increases intracellular glutathione concentrations (an endogenous reducing agent) and/or acts directly as a free radical scavenger (19). NAC has been used in clinical practice since the 1950s for the treatment of congestive and obstructive lung diseases such as chronic bronchitis and cystic fibrosis. Furthermore, exploratory studies are being performed in the treatment of a variety of immune and inflammatory disorders, such as human immunodeficiency virus infection (reviewed in Ref. 20).
LPS stimulates NF-
B DNA-binding activity, phospholipase release and activity, PGF2
production, and proinflammatory cytokine release from human fetal membranes (21, 22, 23, 24, 25, 26, 27). The aim of this study was to investigate whether NAC suppresses LPS-stimulated NF-
B DNA-binding activity and subsequent phospholipid metabolism, proinflammatory cytokine release, and protease activity from human amnion and choriodecidua.
| Materials and Methods |
|---|
|
|
|---|
All chemicals were purchased from BDH Chemicals Australia (Melbourne, Australia) unless stated otherwise. RPMI 1640 (phenol red free) was obtained from Life Technologies, Inc. (Grand Island, NY). BSA (RIA grade), dithiothreitol, EDTA, gelatin, leupeptin, LPS (from Escherichia coli 026:B6), ß-NADH (disodium salt), 3,3',5,5'-tetramethylbenzidine, pyruvic acid (dimer free), and NAC were supplied by Sigma-Aldrich (St. Louis, MO). Pefabloc SC (4-(2-aminoethyl)-benzenesulfonyl fluoride, hydrochloride) was purchased from Roche (Mannheim, Germany). The transcription factor consensus oligonucleotides for NF-
B (5'-AGTTGAGGGGACTTTCCCAGGC-3') and activating protein-1 (5'-TTCCGGCTGACTCATCAAGCG-3'), HeLa scribe nuclear extract, gel shift binding buffer, and polynucleotide kinase for labeling of 5'-hydroxyl blunt-ended probes were purchased from Promega Corp. (Madison, WI). Streptavidin-horseradish peroxidase conjugate and the IL-6, IL-8, and TNF
kits were supplied by Biosource Technologies, Inc. (Camarillo, CA). The 8-isoprostane kit was purchased from Caymen Chemical Co. (Ann Arbor, MI). Human plasminogen (Glu type), MMP-9, and uPA standard were purchased from Calbiochem (San Diego, CA). Acrylamide, ammonium persulfate, bis-acrylamide, Coomassie Brilliant Blue, Rainbow protein molecular weight markers, N,N,N,N'-tetramethylethylenediamine, and [
-32P]deoxy-ATP were purchased from Amersham Pharmacia Biotech (Little Chalfont, UK). Alkaline phosphatase (calf intestine grade 1) was obtained from Roche Molecular Biochemicals (Victoria, Australia). Monoclonal antibodies to human type II PLA2 (3G3 and 2A9) were supplied by Bioquest (Sydney, Australia) and recombinantly expressed human type II PLA2 standard was isolated from a Chinese hamster ovary cell line stably transfected with human type II PLA2 under a metallothionine promoter. Starscint scintillation fluid was purchased from Packard (Meriden, CT), and phenol was obtained from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Human
-globulin was provided by Commonwealth Serum Laboratories (Parkville, Australia). Goat polyclonal antiserum raised against PGF2
was provided by Dr. Meg Ralph (Monash University, Clayton, Australia).
Tissue collection and preparation
Human placentas with the attached fetal membranes were obtained (with institutional research and ethics committee approval) from women who delivered healthy, singleton infants at term (
37 wk gestation) undergoing elective cesarean section (indications for cesarean section were breech presentation and/or previous cesarean section). A human explant system was used to establish the effect of NAC on phospholipid metabolism, proinflammatory cytokine release, ECM remodeling enzyme activity, and NF-
B DNA-binding activity from human fetal membranes as previously described (27). Amnion and choriodecidual tissues were incubated in duplicate in 2 ml RPMI (containing 100 U/ml penicillin G, 100 µg/ml streptomycin, and 10 µg/ml LPS) in the absence (control) or presence of 5, 10, or 15 mM NAC (n = 9).
Nuclear protein extraction and EMSA
After the 6-h incubation, tissues were collected, and nuclear protein was extracted as previously described (27). Nuclear protein (12 µg) was then subjected to EMSA using a double-stranded NF-
B oligonucleotide that was end-labeled using T4 polynucleotide kinase and [
-32P]ATP (27). After electrophoresis, the gel was dried and exposed to Kodak X-OMAT AR film (Eastman Kodak Co., Rochester, NY) overnight at -80 C. Autoradiographs were quantified with a GS-800 calibrated densitometer (Bio-Rad Laboratories, Inc., Richmond, CA) using the Quantity One 4.2.1 analysis program. Data were corrected for background and expressed as OD per square millimeter.
Experimental assays
Type II PLA2 tissue content and the release of PFG2
from fetal membranes were quantified by ELISA and RIA, respectively, as previously described (28). The release of IL-6, IL-8, and TNF
from fetal membrane tissue explants was quantified by ELISA kits according to the manufacturers instructions (Biosource Technologies, Inc.), and the limits of detection of the IL-6, IL-8, and TNF
assays were 3, 2.8, and 7.2 pg/ml, respectively. Assessment of ECM remodeling enzymes in fetal membranes were performed by electrophoretic zymography as previously described (29), and enzyme activities were identified by comigration with authentic standards and comparison with the mobility of protein standards. Proteolytic activity was visualized as clear zones of lysis on a blue background of undigested gelatin. The release of 8-isoprostane into the incubation medium was assayed using a competitive enzyme immunoassay, according to the manufacturers instructions (Cayman Chemical Co.), and the limit of detection of the assay was 5 pg/ml. The protein content of tissue homogenates was determined with a bicinchoninic acid protein assay (Pierce Chemical Co., Rockford, IL), using BSA as a reference standard, as previously described (27). To determine the effect of experimental treatment on cell membrane integrity, the release of the intracellular enzyme lactate dehydrogenase (LDH) into the incubation medium was determined as described previously (22). Data are presented as a percentage of the total tissue LDH.
Statistical analysis
Statistical analyses were performed using a commercially available statistical software package (Statgraphics, STSC, Rockville, MD). The homogeneity of data was assessed by Bartletts test (30), and when significant, data were logarithmically transformed before further analysis. Data were subjected to a one-way ANOVA. Two-sample comparisons were analyzed by t test. Statistical difference was indicated by P < 0.05. Data are expressed as the mean ± SEM of nine different placental tissues.
| Results |
|---|
|
|
|---|
To validate the integrity of explants in the presence of NAC, cell viability was investigated using LDH release from explants. LDH release was investigated over the 6-h incubation period. Explants were incubated in either control medium (10 µg/ml LPS) or medium containing 5, 10, or 15 mM NAC. Compared with the LPS control, treatment with NAC, at all concentrations tested, did not significantly affect LDH release from amnion and choriodecidua, indicating that the concentration of NAC used did not affect cell viability (Table 1
).
|
B-binding activity
Previous studies within our laboratory have demonstrated NF-
B DNA-binding activity in nuclear extracts fromhuman fetal membranes (27). Furthermore, the specificity of NF-
B DNA binding was confirmed in competition experiments. Supershift assays also established that the NF-
B p50 and p65 heterodimers are activated in gestational tissues in response to LPS. In this study treatment with 10 and 15 mM NAC significantly suppressed NF-
B DNA-binding activity in nuclear extracts prepared from human amnion (Fig. 1A
) and choriodecidua (Fig. 1B
).
|
In the presence of 10 or 15 mM NAC, type II PLA2 content was significantly inhibited in amnion (Fig. 2A
) and choriodecidua (Fig. 2B
). At 15 mM NAC, there were 4- and 2-fold decreases in the level of type II PLA2 content in amnion and choriodecidua, respectively.
|
in amnion (Fig. 3A
|
Compared with LPS control, tissues incubated in the presence of NAC greater than or equal to 10 mM caused a significant reduction of IL-6 release from amnion and choriodecidua (Fig. 4A
). In the presence of 15 mM NAC, there was a 3-fold reduction in the release of IL-6 from both amnion and choriodecidua.
|
In amnion, concentrations greater than 5 mM NAC significantly reduced TNF
release, with a 3-fold reduction observed at 15 mM NAC (Fig. 4C
). In choriodecidua, 15 mM NAC significantly reduced TNF
release, with a 3-fold decrease (Fig. 4C
).
Effect of NAC on proteolytic activity
Gelatin substrate gels copolymerized with plasminogen were used to determine the effect of NAC on protease activity in human fetal membranes. In both amnion and choriodecidua (Fig. 5A
), the addition of 15 mM NAC significantly suppressed MMP-9 activity. Compared with the LPS control, concentrations of NAC equal to or greater than 10 mM significantly suppressed uPA activity in both amnion and choriodecidua (Fig. 5B
).
|
The release of 8-isoprostane into the incubation medium is used as a marker of oxidative stress. Treatment with 15 mM NAC reduced LPS-induced 8-isoprostane accumulation into the incubation medium from amnion and choriodecidual tissues (Fig. 6
). Compared with the LPS control, coincubation with 15 mM NAC caused a 3-fold reduction in amnion and a 5-fold decrease in choriodecidua.
|
| Discussion |
|---|
|
|
|---|
, IL-6, IL-8, TNF
, and 8-isoprostane release; and MMP-9 and uPA enzyme activities. Furthermore, this inhibition was associated with a concomitant suppression of NF-
B DNA-binding activity. Similarly, others have demonstrated that NAC inhibits the expression, release, and/or activity of proinflammatory cytokines and MMPs through suppression of NF-
B activation in a number of other systems (31, 32, 33, 34, 35, 36). Similarly, the use of other antioxidants, for example, pyrrolidine dithiocarbamate, have also demonstrated the importance of the NF-
B signaling pathway in the regulation of cytokine release and protease activity (34, 35).
Although there is no common second messenger among the identifiable inducers of NF-
B, most, if not all, activating signals can be inhibited by antioxidants (reviewed in Ref. 5), suggesting that ROS act as second messengers after cellular exposure to agents that induce NF-
B activation. The interaction between ROS on the NF-
B signaling pathway has not been completely defined; nevertheless, the most likely scenario is that ROS activates a critical redox-sensitive kinase, probably by the I
B kinase or NF-
B-inducing kinase signals (reviewed in Ref. 37).
As ROS have been implicated in the pathogenesis of preterm labor (reviewed in Ref. 3), and as PGs, proinflammatory cytokines, and proteases are also involved in the pathogenesis of preterm labor, interactions between ROS and NF-
B might be a component of the intracellular signaling processes that lead to activation.
The data obtained in this study are consistent with and extend studies implicating NF-
B in the regulation of human gestational tissue proinflammatory status (27). Our data establish a role for NF-
B in regulating type II PLA2 and subsequent PG production, which are intrinsic for successful parturition. Similarly, other studies have also demonstrated the importance of NF-
B in regulating components of the phospholipid-metabolizing pathway in human gestational tissues (15, 38).
A growing body of evidence suggests that membrane rupture is partially mediated by biochemical processes, including the enzymatic breakdown of ECM components within the amnion and chorion. MMP-9 and uPA are key enzymes involved in the breakdown of these ECM components within the amnion and chorion. PPROM may be the result of ROS-induced damage to amnion epithelium or collagen in the chorioamnion (reviewed in Ref. 3). Various environmental and physical factors associated with PPROM are known to produce ROS or reduce the bodys natural antioxidant defense mechanisms (e.g. smoking and cocaine abuse). In a recent in vitro study, the treatment of chorioamnion with antioxidants, including NAC, protected against ROS-induced MMP-9 activity (reviewed in Ref. 3). Similarly, in this study incubation of amnion and choriodecidua with NAC inhibited LPS-stimulated NF-
B activation of MMP-9 and uPA activities, with an associated decrease in 8-isoprostane. It is conceivable that therapies that suppress NF-
B activation may be useful in the prevention of PPROM; however, further studies are required to evaluate antioxidant therapy for the prevention of PPROM.
ROS can be generated by a number of sources, including leakage from the electron transport system in the inner membrane of a mitochondrion during cellular respiration and release by immune cells as they encircle and then kill bacteria. One of the most important sources of ROS in macrophages in response to LPS stimulation is the membrane-bound NADPH oxidase activation that occurs during phagocytosis (reviewed in Ref. 5). In response to a phagocytic stimuli, NADPH oxidase moves electrons from NADPH to reduce oxygen to superoxide. Superoxide is regarded as a weakly reactive radical, but nonetheless can attack a number of biological targets. Superoxide is removed from tissues by spontaneous dismutation to hydrogen peroxide (a process that can also be catalyzed by superoxide dismutase), then oxygen, and then sequentially to other products. However, the exact mechanism for LPS-induced ROS generation remains to be fully established.
A number of studies have identified NF-
B DNA-binding activity in human gestational tissues (14, 15, 27, 38, 39, 40). NF-
B is essential for up-regulation of IL-8 expression in human amnion-derived WISH cells and cervical epithelial cells (38, 39). Stimulation of human trophoblast cells with IL-1 leads to NF-
B activation that is functionally linked to the expression of cyclooxygenase-2 and PGs (15). It is likely that the same mechanism is operative in cytokine-induced up-regulation of PG production in gestational tissues, thereby contributing to the labor-inducing effects of proinflammatory cytokines.
These results confirm that ROS are involved in LPS-stimulated NF-
B activation and the subsequent genes that it regulates. In this study we demonstrate that in human fetal membranes, the NF-
B signaling pathway is a key regulator of phospholipid metabolism, proinflammatory cytokines, and ECM-remodeling enzymes. Consequently, the development of specific inhibitors of NF-
B will be beneficial in further dissecting the role of NF-
B in the initiation of human labor and could potentially be clinically useful in the management and/or treatment of preterm labor associated with infection.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: ECM, Extracellular matrix; LDH, lactate dehydrogenase; LPS, lipopolysaccharide; MMP, matrix metalloproteinase; NAC, N-acetyl-cysteine; NF-
B, nuclear factor-
B; PGF2
, prostaglandin F2
; PLA2, phospholipase A2; PPROM, prolonged premature rupture of membranes; ROS, reactive oxygen species; uPA, urokinase-type plasminogen activator.
Received October 25, 2002.
Accepted January 6, 2003.
| References |
|---|
|
|
|---|
B and I
B proteins: new discoveries and insights. Annu Rev Immunol 14:649681[CrossRef][Medline]
promoter in primary macrophages. J Immunol 147:16941700[Abstract]
B and AP-1. Am J Physiol 270:F123F130
B in cytokine gene regulation. Am J Respir Cell Mol Biol 17:39
B activation and IL-6 production in fibroblasts by estrogen receptor-negative breast cancer cell-derived interleukin-1
. Proc Natl Acad Sci USA 95:69716976
B and peroxisome proliferator-activated receptor-mediated process. J Biol Chem 274:2308523093
B. Carcinogenesis 21:17451751
B activation prohibits TNF-
induced cyclooxygenase-2 gene expression in ED27 trophoblast-like cells. Placenta 22:8089[CrossRef][Medline]
B in lipopolysaccharide-stimulated U937 cells. Biochem Pharmacol 53:339346[CrossRef][Medline]
B translocation and requires protein synthesis. J Leukocyte Biol 63:509514[Abstract]
B inhibition. J Immunol 162:25692574
B regulation of pro-inflammatory cytokines in human gestational tissues in vitro. Biol Reprod 67:668673
mediated stimulation of interleukin-8, monocyte chemoattractant protein-1, and collagenase expression in cultured human synovial cells. J Rheumatol 23:432438[Medline]
B activation and cytokine production by N-acetylcysteine in pancreatic acinar cells. Free Radic Biol Med 29:674683[CrossRef][Medline]
induce NF-
B-DNA binding in primary human T lymphocytes in addition to T cell lines. Free Radic Res 35:681691[CrossRef][Medline]
via NF-
B-mediated pathway. Am J Physiol 281:L1444L1452
B and AP-1 are required for cyclo-oxygenase 2 gene expression in amnion epithelial cell line (WISH). Mol Hum Reprod 6:561565
B mediates interleukin-1ß-induced expression of cyclooxygenase-2 in human myometrial cells. Am J Obstet Gynecol 181:359366[CrossRef][Medline]
B pathway in human endometrium and first trimester decidua. Mol Hum Reprod 7:175183This article has been cited by other articles:
![]() |
M. Colomiere, M. Permezel, C. Riley, G. Desoye, and M. Lappas Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus Eur. J. Endocrinol., April 1, 2009; 160(4): 567 - 578. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Moore, J. B. Novak, D. Kumar, J. M. Mansour, B. M. Mercer, and J. J. Moore Alpha-Lipoic Acid Inhibits Tumor Necrosis Factor-Induced Remodeling and Weakening of Human Fetal Membranes Biol Reprod, April 1, 2009; 80(4): 781 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Joyce, A. Cook, J. Newnham, M. Brenters, C. Ferguson, and P. Weinstein Water Disinfection By-Products and Prelabor Rupture of Membranes Am. J. Epidemiol., September 1, 2008; 168(5): 514 - 521. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Herve, T. Schmitz, D. Evain-Brion, D. Cabrol, M.-J. Leroy, and C. Mehats The PDE4 Inhibitor Rolipram Prevents NF-{kappa}B Binding Activity and Proinflammatory Cytokine Release in Human Chorionic Cells J. Immunol., August 1, 2008; 181(3): 2196 - 2202. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.M. Mitchell, R.F. Johnson, W.B. Giles, and T. Zakar Prostaglandin H synthase-2 gene regulation in the amnion at labour: histone acetylation and nuclear factor kappa B binding to the promoter in vivo Mol. Hum. Reprod., January 1, 2008; 14(1): 53 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alipour, A. Omri, M. G. Smith, and Z. E. Suntres Prophylactic effect of liposomal N-acetylcysteine against LPS-induced liver injuries Innate Immunity, October 1, 2007; 13(5): 297 - 304. [Abstract] [PDF] |
||||
![]() |
M. Lappas, M. Permezel, and G. E Rice Advanced glycation endproducts mediate pro-inflammatory actions in human gestational tissues via nuclear factor-{kappa}B and extracellular signal-regulated kinase 1/2 J. Endocrinol., May 1, 2007; 193(2): 269 - 277. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M Lindstrom and P. R Bennett The role of nuclear factor kappa B in human labour Reproduction, November 1, 2005; 130(5): 569 - 581. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Chapman, I. Smyrnias, D. O. C. Anumba, G. N. Europe-Finner, and S. C. Robson Expression of the GTP-Binding Protein (G{alpha}s) Is Repressed by the Nuclear Factor {kappa}B RelA Subunit in Human Myometrium Endocrinology, November 1, 2005; 146(11): 4994 - 5002. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lappas, K. Yee, M. Permezel, and G. E. Rice Sulfasalazine and BAY 11-7082 Interfere with the Nuclear Factor-{kappa}B and I{kappa}B Kinase Pathway to Regulate the Release of Proinflammatory Cytokines from Human Adipose Tissue and Skeletal Muscle in Vitro Endocrinology, March 1, 2005; 146(3): 1491 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Coughlan, M. Permezel, H. M. Georgiou, and G. E. Rice Repression of Oxidant-Induced Nuclear Factor-{kappa}B Activity Mediates Placental Cytokine Responses in Gestational Diabetes J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3585 - 3594. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Lappas, M. Permezel, H. M. Georgiou, and G. E. Rice Regulation of Phospholipase Isozymes by Nuclear Factor-{kappa}B in Human Gestational Tissues in Vitro J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2365 - 2372. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |